Descripción
The fully automatic MAGLUMI SARS-CoV-2 Neutralizing Antibody Assay aims to detect neutralizing antibodies against the SARS-CoV-2, which indicate the immune status of the vaccine receivers and the COVID-19 patients. Different from the traditional neutralizing antibody detection method-the plaque reduction neutralization test (PRNT) which requires BSL-3 laboratories and may take up to five days to complete, the assay is capable of providing the first result within 20 minutes when combined with MAGLUMI CLIA analyzers.